Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Council Members who Treat Colon/Colorectal Cancer

Articles with lock require a subscription to GLG News | Request a free trial
September 8, 2008
Think about the future and what this will lead to....
Analysis of: In Long-Awaited Maps of Cancer, The Breakthrough Is the Problem | online.wsj.com
Author: GLG Expert Contributor
Pharmacogenomics will lead to the development of targeting agents and offer true hope for the future.
September 2, 2008
GIST: So what else is new.....
Analysis of: Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Novartis is looking for approval for therapy in C-KIT + Gastrointestinal stromal tumors
August 29, 2008
Bcl-2 apoptosis inhibition: The next "best" thing?
Analysis of: Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents | jco.ascopubs.org
Author: GLG Expert Contributor
Bcl-2 inhibition by small molecules stands to be the next avenue for antineoplastic therapy- Looks like the real deal!
August 29, 2008
Amgen Rewords Label: Less Use of Procrit
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
The FDA required Amgen to revise the label for Procrit and Aranesp so that these agents are not used until a patient's hemoglobin drops below 10 or in the setting of potentially curative therapy.
August 29, 2008
Transparency in Healthcare: How to Assess?
Analysis of: Transparency in Healthcare | www.hospitalimpact.org
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
The author argues that transparency in healthcare will be an important step forward for the consumer.
August 29, 2008
Avastin: Worth the Cost?
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Avastin improves survival in colon cancer and lung cancer and improves progression free survival in breast cancer- clinically meaningful outcomes.  Yet these gains are of relatively short duration and the cost of Avastin is significant- 50,000 to 100,000 dollars per year.
August 29, 2008
So Much for GVAX.... for now?
Analysis of: Cell Genesys Ends Clinical Trials For Prostate Cancer Treatment | online.wsj.com
Author: GLG Expert Contributor
No reason for the increased mortality vs Chemo alone was identified. Cell Genesys is looking into where to go now.
August 29, 2008
Velcade in myeloma 1st line. Am I s?urprised
Analysis of: Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma | content.nejm.org
Author: GLG Expert Contributor
Velcade + classic Melphalan/ Prednisone  (MP) is better than MP alone. No surprise
August 28, 2008
NICE States Novel Therapies for Renal Cell Cancer Too Costly
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
NICE has stated that the cost of several novel agents for the treatment of renal cell cancer including Sutent, Torisel, Avastin, and Nexavar exceeds the benefit when assessed by quality adjusted life years (QALY) gained from the therapies.
August 25, 2008
Amgen's long awaited product to treat chronic ITP will be well receive.
Analysis of: Amgen Blood-Disorder Drug Gains Clearance | online.wsj.com
Author: GLG Expert Contributor
Chronic ITP is not all that uncommon and becomes a quality of life issue with chronic steroid use as well as agents that are normaly used in neoplasia and even derivatives of male hormones.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next41 to 50 of 660

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T17:45:17.163